1

Taisho Pharmaceutical

#2813

Rank

$4.48B

Marketcap

JP Japan

Country

Taisho Pharmaceutical
Leadership team

Mr. Akira Uehara (CEO & Representative Director)

Mr. Ken Uehara (MD & Exec. Director)

Mr. Shigeru Uehara (Exec. VP & Director)

Products/ Services
Biotechnology, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Tokyo, Tokyo, Japan
Established
1912
Net Income
100M - 500M
Revenue
Above - 1B
Traded as
4581.T
Overview
Location
Summary
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.
History

Taisho was established in 1912 as Taisho Seiyakusho to produce over-the-counter drugs. In 1928 the company changed its name to Taisho Pharmaceutical Co., Ltd. and in 1955 moved into prescription drug R&D. It introduced its over-the-counter medications like cough suppressant in 1927, pain reliever in 1967 and an antiulcer agent in 1984. In 2019 Taisho bought French pharmaceutical manufacturer UPSA from Bristol-Myers Squibb.

Mission
Our mission is to care for people’s health, provide daily conveniences, and create a comfortable life for all through our products.
Vision
Our vision is to create a rich, healthy living environment for people around the world through our products, services, and innovations.
Key Team

Shinichi Tanaka (Gen. Mang. of Corp. Communications)

Mr. Tetsu Watanabe (Exec. Director)

Mr. Jun Kuroda (Exec. VP & Director)

Hisashi Umeoka (Director)

Hideki Iuchi (Gen. Mang.)

Jinsei Maruyama (Corp. Officer)

Recognition and Awards
Taisho Pharmaceutical Co., Ltd. has been the recipient of a number of awards over the years, including the Japan Quality Award and the National Award of Merit. The company has also been recognized on the international stage, having been awarded the PMDA Innovative Products Award and the USP Quality Excellence Award.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Taisho Pharmaceutical
Leadership team

Mr. Akira Uehara (CEO & Representative Director)

Mr. Ken Uehara (MD & Exec. Director)

Mr. Shigeru Uehara (Exec. VP & Director)

Products/ Services
Biotechnology, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Tokyo, Tokyo, Japan
Established
1912
Net Income
100M - 500M
Revenue
Above - 1B
Traded as
4581.T